Tesamorelin vs Semaglutide: Two Different Axes for Visceral Fat on TRT

Tesamorelin and semaglutide are often discussed as alternatives for visceral fat reduction, but they work on different physiological axes with different downstream consequences.

Tesamorelin is a synthetic GHRH analog that triggers endogenous pulsatile GH release. Visceral fat reduction comes from GH-mediated lipolysis: GH preferentially mobilises visceral adipocytes because visceral fat has higher GH receptor density than subcutaneous fat. The mechanism does not require caloric restriction. Lean mass is preserved or slightly increased.

Semaglutide is a GLP-1 receptor agonist. It reduces visceral fat through caloric deficit driven by appetite suppression, delayed gastric emptying, and improved satiety. The mechanism is downstream of energy balance, not specific to visceral fat. Lean mass loss is a documented consequence of the caloric deficit (8-11% in body composition substudies of STEP 1 and SURMOUNT-1).

The two are not redundant. For a TRT user with metabolic syndrome and stubborn VAT, the optimal stack often pairs tesamorelin (for the GH-mediated visceral lipolysis with lean mass preservation) with a low-dose GLP-1 (for the caloric discipline that drives broader weight loss).

Mechanism:

• Tesamorelin: GHRH receptor agonist, pulsatile GH release, GH-mediated visceral lipolysis
• Semaglutide: GLP-1 receptor agonist, appetite suppression, caloric deficit driven

Route and convenience:

• Tesamorelin: subcutaneous injection, daily
• Semaglutide: subcutaneous injection, weekly

Evidence base:

• Tesamorelin: FDA-approved 2010 (HIV lipodystrophy); Phase 3 RCT in 806 patients (Falutz 2010)
• Semaglutide: FDA-approved 2017 (T2D, Ozempic); 2021 (obesity, Wegovy); Phase 3 STEP program (Wilding 2021, PMID 33567185)

Visceral fat reduction:

• Tesamorelin: -15.2% to -15.4% VAT at 26 weeks (Falutz 2007, Stanley 2014)
• Semaglutide 2.4 mg/week: significant VAT reduction documented in STEP 1 body composition substudy and STEP 6 in Japanese cohort

Total body weight change:

• Tesamorelin: minimal change in body weight at 26 weeks (the effect is selective to visceral fat, not total adiposity)
• Semaglutide 2.4 mg/week: -14.9% body weight at 68 weeks (STEP 1)

Lean mass impact:

• Tesamorelin: preserved or slightly increased (+1.3 kg lean mass in Falutz 2007)
• Semaglutide: 8-11% lean mass loss documented in body composition substudies (the lean mass tax of caloric deficit)

Glucose and insulin sensitivity:

• Tesamorelin: neutral over 52 weeks (Falutz 2010)
• Semaglutide: improves glucose, reduces HbA1c, improves insulin sensitivity (the GLP-1 metabolic benefit)

Triglycerides:

• Tesamorelin: -50 mg/dL at 26 weeks (responders)
• Semaglutide: lipid improvements driven by weight loss

IGF-1:

• Tesamorelin: +81% to +108 ng/mL absolute
• Semaglutide: no direct effect on GH/IGF-1 axis

Appetite:

• Tesamorelin: no appetite effect
• Semaglutide: significant appetite suppression (the dominant mechanism)

Cost:

• Tesamorelin (Egrifta brand): USD $2,000+/month; grey market USD $300-500/month
• Semaglutide (Wegovy/Ozempic): USD $1,000+/month; compounded USD $250-500/month

Side effects:

• Tesamorelin: injection-site reactions, transient arthralgia, small IGF-1 ceiling concern
• Semaglutide: gastrointestinal (nausea, constipation, delayed gastric emptying), rare pancreatitis, gallbladder concerns

Choose tesamorelin alone if:

• You are at goal body weight but have stubborn visceral fat
• Your bloodwork shows metabolic syndrome (high TG, central adiposity) but body weight is not the problem
• You want to preserve or build lean mass
• You have NAFLD or fatty liver from oral AAS history
• You do not need or want appetite suppression

Choose semaglutide alone if:

• You need significant total weight loss (>10%)
• Appetite control is the dominant problem
• You are okay with the lean mass cost (8-11% lean mass loss)
• You want the improved glucose and HbA1c benefits
• Your visceral fat is part of a broader obesity problem, not isolated

Stack tesamorelin plus low-dose semaglutide if:

• You have metabolic syndrome plus stubborn visceral fat on TRT
• You want both the GH-mediated visceral lipolysis (tesamorelin) and the caloric deficit (low-dose semaglutide 0.5-1.0 mg/week)
• You want to protect lean mass while running the GLP-1 (tesamorelin's lean mass preservation offsets the GLP-1's lean mass tax)
• You can monitor both compounds carefully (IGF-1, glucose, HbA1c for tesamorelin; lipase, amylase, GI tolerance for semaglutide)

For TRT users with isolated visceral fat: Tesamorelin is the better single-agent choice. The Mangili 2015 sub-analysis identifies the metabolic syndrome subgroup as the biggest responders.

For TRT users with general obesity plus visceral fat: The stack is mechanistically optimal.